Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Masahiko Mihara1, Yoshiyuki Ohsugi2, Tadamitsu Kishimoto31Product Research Department, Chugai Pharmaceutical Co Ltd, Fuji-Gotemba Research Laboratories, Shizuoka, Japan; 2Chugai Pharmaceutical Co Ltd, Tokyo, Japan; 3Laboratory of Immunoregulation, Graduate School of Frontier Biosciences, Osaka Unive...
Saved in:
Main Authors: | Masahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/12b0bcddd7234a7d999bf1771ed9a2a2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation
by: Townes SV, et al.
Published: (2012) -
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
by: Murakami M, et al.
Published: (2012) -
Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis
by: Sebba A
Published: (2021) -
Rheumatoid arthritis: Disease or syndrome?
by: Jessica A Stanich, et al.
Published: (2009) -
Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis
by: Takahashi R, et al.
Published: (2014)